|Bid||9.40 x 900|
|Ask||9.98 x 1000|
|Day's Range||9.50 - 9.50|
|52 Week Range||8.27 - 14.00|
|Beta (3Y Monthly)||0.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.43|
- Total Second Quarter Revenues Increase 21% to $7.4 Million - - WatchPATTM Revenues Increase 16% in the Second Quarter to $6.5 Million - - Company to Host Conference Call.
Itamar Medical Ltd. (ITMR) (ITMR.TA), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, announced today that it will report its unaudited financial results for the second quarter of 2019 before the U.S. market opens on Wednesday, August 14, 2019. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO.
TEL AVIV, Israel , June 26, 2019 /PRNewswire/ -- Itamar Medical's (NASDAQ: ITMR) (TASE: ITMR) revolutionary technology enables cardiologists to make better decisions and results in 30% assumed revenue ...
Itamar Medical Ltd. (ITMR) (ITMR.TA), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for WatchPAT One, the latest innovation of its WatchPAT technology and the first and only fully disposable Home Sleep Apnea Test (HSAT). WatchPAT One incorporates the technology and comfort advances of WatchPAT 300, which received 510(k) clearance in August 2018 and was launched in March 2019.
Itamar Medical Ltd. (NASDAQ and TASE:ITMR), a company that develops, manufacturers and markets non-invasive diagnostic devices for sleep apnea with a focus on the cardiology market, and BioTel Heart, a division of BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced an expanded collaboration to make Itamar Medical’s Total Sleep Solution available to select BioTel Heart cardiology customers in the United States. The collaboration is designed to respond to the growing demand for home sleep apnea testing among cardiologists, who recognize effective sleep apnea management as a critical strategy for improving health in patients with cardiac disease.
- WatchPAT™ Revenues Increase 15% to $5.8 Million - - U.S. WatchPAT Revenues Increase 34% to $4.3 Million - - Total Revenues Increase 11% to $6.1 Million - CAESAREA, Israel,.
Itamar Medical Ltd. (Nasdaq & TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced the launch of WatchPAT 300, the next generation WatchPAT system for home sleep apnea testing. WatchPAT 300 includes several advances that are designed to enhance both patients’ WatchPAT experience as well as provide physicians with a trusted and cost-effective method for rapid, scalable and effective diagnosis of sleep apnea. “Sleep apnea has reached epidemic levels and is estimated to affect 25 percent of adults worldwide,” said Gilad Glick, President and CEO of Itamar Medical.
Full Year 2018 Revenues Increased 17% to $24.2 Million; WatchPAT™ Revenues Increased 24% to $22.4 Million Fourth Quarter 2018 Revenues Increased 9% to $6.6 Million; WatchPAT.
CAESAREA, Israel, March 12, 2019 -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical device company that develops, manufactures and markets non-invasive diagnostic.